NEOPHOTONICS CORP

Operating margin

−62.1%

Net margin

−17.5%

Return on equity

−7.0%

Return on assets

−3.5%

Return on capital (ROCE)

−19.0%

Liabilities / assets

49.9%

Debt / equity

1.00×

Book value / share

$3.01

Revenue growth (YoY)

−37.4%

Net income growth (YoY)

−269.5%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

-2.02distress

Accruals / assets

3.2%clean

Piotroski F-Score

0/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 3, 2022
• Entered a material agreement · New financial obligationAug 2, 2022
• Other material eventJul 29, 2022
• Results of operationsJul 25, 2022
• Director / officer changeJul 7, 2022
• Shareholder voteJun 6, 2022
• Results of operationsApr 28, 2022
• Completed an acquisition or dispositionFeb 24, 2022

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.